DBV Technologies H1 2026 net loss $98M; BLA submission for peanut patch delayed to Q3 2026

DBV Technologies S.A.

2026-Q2 EPS reported -$0.23 vs consensus -$0.10 ▼ miss (-127.7%)

Net loss of $98.0M for H1 2026 vs $69.0M for H1 2025; Q2 net loss $50.4M.
Cash and equivalents $174.9M as of June 30, 2026, funding into Q3 2027.
BLA submission for VIASKIN Peanut Patch (ages 4-7) now expected in Q3 2026, previously Q2.
R&D expenses $64.6M in H1 2026, up from $55.2M, driven by clinical trials and BLA prep.
SG&A expenses rose to $25.1M from $14.1M due to commercial infrastructure build.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.